240486-10-6

Basic information

• Product Name: ethyl 4-(2-bromophenylamino)-4-cyano-1-piperidinecarboxylate
• CAS NO: 240486-10-6
• Molecular Weight: 352.231
• Mol File: 240486-10-6.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: ethyl 4-(2-bromophenylamino)-4-cyano-1-piperidinecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-(2-bromophenylamino)-4-cyano-1-piperidinecarboxylate(240486-10-6)
• EPA Substance Registry System: ethyl 4-(2-bromophenylamino)-4-cyano-1-piperidinecarboxylate(240486-10-6)

Safety Data

• Hazardous Substances Data: 240486-10-6(Hazardous Substances Data)

Upstream product

• 7677-24-9 trimethylsilyl cyanide 
• 29976-53-2 N-ethoxycarbonyl-4-piperidone 
• 615-36-1 2-bromoaniline 

Downstream Products

• 1050595-96-4 N-(2-{[(2S)-3-({spiro[indole-2-4'-piperidin]-3(1H)-one}-1'-yl)-2-hydroxypropyl]oxy}-4-hydroxyphenyl)acetamide 
• 84145-25-5 4-cyano-4-phenylamino-piperidine-1-carboxylic acid ethyl ester 
• 240486-16-2 ethyl 1,3-dihydro-3-imino-spiro[2H-indole-2,4'-piperidine]-1'-carboxylate 
• 240486-28-6 C₂₂H₂₄N₂O₃ 

Relevant articles and documents

NOVEL COMBINATION OF COMPOUNDS TO BE USED IN THE TREATMENT OF AIRWAY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA

The present invention provides a pharmaceutical product comprising, in combination of, (a) a (therapeutically effective) dose of a first active ingredient, which is a compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) a (therapeutically effective) dose of a second active ingredient, which is a glucocorticoid receptor agonist; and optionally, (c) a (therapeutically effective) dose of a third active ingredient, which is a β2-agonist. The invention further relates to pharmaceutical compositions comprising said combination and to methods of treating treatment of airway diseases, especially chronic obstructive pulmonary disease (COPD) and asthma in mammals by administrating said combination. The invention further relates to a kit comprising the combination and use of said kit in treatment of airway diseases such as COPD and asthma.